- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03446092
Mindfulness for People With Incurable Cancer
A Pilot Investigation of a Mindfulness Course for People With Incurable Cancer
Study Overview
Detailed Description
It can be hard to come to terms with living with a life limiting condition such as incurable cancer and individuals are at risk of experiencing high levels of psychological distress, which can often be overlooked when the focus is on managing physical symptoms.
Mindfulness-based interventions have been shown to be helpful in reducing distress for people with cancer generally. This pilot study will use an established mindfulness programme called mindfulness for health with people with cancer which is incurable to see if this type of intervention is acceptable and useful for this group of people.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lancaster, United Kingdom
- Royal Lancaster Infirmary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Deemed by the oncologist to have incurable cancer
- Patient of the University Hospitals of Morecambe Bay NHS Foundation Trust
- Treated by an oncologist
- Believe they are able to commit to attending most of the mindfulness course sessions
- Oncologist assesses they are well enough to participate in the intervention
Exclusion Criteria:
- Having any other condition or difficulty which the medical team thinks would compromise their participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness group
Group will receive mindfulness intervention
|
A course of mindfulness using the mindfulness for health programme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability and usefulness of intervention for participants
Time Frame: Within 4 weeks of the end of the intervention
|
This will be a qualitative outcome, collected via semi-structured interview
|
Within 4 weeks of the end of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability and usefulness of intervention for participants- 3 months
Time Frame: 3 months following completion of the intervention
|
This will be a qualitative outcome, collected via semi-structured interview
|
3 months following completion of the intervention
|
Change in depression anxiety and stress
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Using the Depression, Anxiety and Stress (DASS21) scale we will measure the change post intervention score - pre intervention score.
Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating higher distress.
A greater decrease in scores, would mean a greater improvement in symptoms.
|
Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Change in depression anxiety and stress-3 months
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and 3 months after the end of the intervention
|
Using the Depression, Anxiety and Stress (DASS21) scale we will measure the change post intervention score - pre intervention score.
Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating higher distress.
A greater decrease in scores, would mean a greater improvement in symptoms.
|
Collected before the intervention (up to 4 weeks before the intervention) and 3 months after the end of the intervention
|
Change in mindfulness
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Using the Five Factor Mindfulness Questionnaire we will measure pre-post change scores.
|
Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Change in mindfulness- 3 months
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and 3 months following the intervention
|
Using the Five Factor Mindfulness Questionnaire we will measure pre-post change scores
|
Collected before the intervention (up to 4 weeks before the intervention) and 3 months following the intervention
|
Change in quality of life
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire we will measure pre-post change scores
|
Collected before the intervention (up to 4 weeks before the intervention) and within 4 weeks of the end of the intervention
|
Change in quality of life - 3 months
Time Frame: Collected before the intervention (up to 4 weeks before the intervention) and 3 months following the intervention
|
Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire we will measure pre-post change scores
|
Collected before the intervention (up to 4 weeks before the intervention) and 3 months following the intervention
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IRASProject ID: 226702
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Mindfulness for health
-
Medical College of WisconsinRecruitingMultiple Myeloma | SleepUnited States
-
Virginia Commonwealth UniversityAmerican Psychological Association (APA)Completed
-
Institut National de la Santé Et de la Recherche...CompletedCognitive DysfunctionFrance, Germany, Spain, United Kingdom
-
Eric LoucksUnknownPhysical Activity | Stress, Psychological | Sleep | Depressive Symptoms | Diet | Sedentary Behavior | Loneliness | Emotional Regulation | Mindfulness | Alcohol Consumption, YouthUnited States
-
Emory UniversitySatellite HealthcareCompletedHypertension | Renal Failure Chronic Requiring Hemodialysis | Haemodialysis-induced SymptomUnited States
-
University of PittsburghNational Institute on Aging (NIA)Completed
-
Johns Hopkins UniversityUniversity of Chicago; Robert Wood Johnson Foundation; Abell Foundation; Elev8...CompletedStress Disorders, Post-Traumatic | Mental Health Wellness 1 | CopingUnited States
-
Carnegie Mellon UniversityUniversity of Pittsburgh; Virginia Commonwealth UniversityCompleted
-
University of California, DavisCompletedKnee OsteoarthritisUnited States